The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
Important safety-related changes to the prescribing information concerning the use of Xeloda in patients with renal impairment at baseline.
[November 28, 2000 - Letter - Roche Pharmaceuticals][November 28, 2000 - Package Insert - Roche Pharmaceuticals]
Page Last Updated: 08/14/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.